摘要
目的:观察强肝胶囊治疗非酒精性脂肪性肝纤维化的疗效。方法:将28例非酒精性脂肪性肝病(NAFLD)患者随机分为2组。对照组12例进行基础护肝治疗,治疗组16例在对照组基础上口服强肝胶囊。2组疗程均为6个月。观察治疗前后2组患者的临床症状、肝功、血清肝纤维化指标、氧化应激指标、活检肝脏病理变化情况。结果:治疗组治疗后谷胱甘肽过氧化物酶(GSH-PX)、超氧化物歧化酶(SOD)、丙二醛(MDA)、玻璃酸(HA)、Ⅲ型前胶原肽(PcⅢ)、Ⅳ型胶原(ⅣC)、层黏蛋白(LN)、基质金属蛋白酶1组织抑制因子(TIMP-1)、病理组织评分与治疗前比较均有明显改善(P<0.01),与对照组治疗后比较差异有统计学意义(P<0.05)。结论:强肝胶囊可以改善肝脏炎症、促进肝内脂肪代谢、保护肝细胞,并对逆转肝纤维化有一定作用,是治疗NAFLD的有效药物之一。
OBJECTIVE： To observe the efficacy of Qianggan capsule in the treatment of nonalcoholic fatty liver. METHODS. 28 patients with nonalcoholic fatty liver disease were randomly divided into experimental group （n=16） and control group （n=12）. Both groups were given basic treatment of hepatoprotective drug for six months. Experimental group were treated with Qianggan capsule additionally. Clinical symptom, hepatic function, the biomarkers of oxidative stess, hepatic fibrosis indicators of 2 groups＇ before and after treatment were observed as well as liver biopsy. RESULTS： As compared with before treatment, experimental group were improved significantly in respects of GSH-PX, SOD, MDA, HA, PcⅢ, ⅣC, LN, TIMP-1, histopathologieal score （P〈0.01）. There were statistical significance in difference between control group and experimental group （P〈0.05）. CONCLUSION： Qianggan capsule can improve hepatic inflammation and fat metabolism in liver to protect hepatocyte and preventing from hepatic fibrosis. It is a satisfactory drug in the treatment of nonalcoholic fatty liver disease.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第8期734-736,共3页
China Pharmacy
关键词
强肝胶囊
非酒精性脂肪性肝病
肝纤维化
Qianggan capsule
Nonalcoholic fatty liver disease
Hepatic fibrosis
